Diagnosing and managing diabetes in HIV-infected patients: Current concepts

Clinical Infectious Diseases

Volumn 60, Issue 3, 2015, Pages 453-462

  Monroe, Anne K ^a   Glesby, Marshall J ^b   Brown, Todd T ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

CVD; diabetes mellitus; HIV

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTITHROMBOCYTIC AGENT; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCRETIN; INSULIN; MEGLITINIDE; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA;

ANTICOAGULANT THERAPY; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIET THERAPY; DISEASE ASSOCIATION; DRUG SUBSTITUTION; EXERCISE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE MODIFICATION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; COMPLICATION; RISK FACTOR; VIROLOGY;

DIABETES MELLITUS; HIV INFECTIONS; HUMANS; RISK FACTORS;

EID: 84922476015     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu779     Document Type: Review

References (75)

1. Centers for Disease Control and Prevention. Crude and age-Adjusted percentage of civilian, noninstitutionalized adults with diagnosed diabetes, United States, 1980-2011. Available at: http://www.cdc.gov/diabetes/statistics/prev/national/figage.htm. Accessed 21 March 2014
2. Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005; 165: 1179-84
3. De Wit S, Sabin CA, Weber R, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients. Diabetes Care 2008; 31: 1224-9
4. Rasmussen LD, Mathiesen ER, Kronborg G, Gerstoft J, Obel N. Risk of diabetes mellitus in persons with and without HIV: a Danish nationwide population-based cohort study. PLoS One 2012; 7: e44575
5. Polsky S, Floris-Moore M, Schoenbaum EE, Klein RS, Arnsten JH, Howard AA. Incident hyperglycaemia among older adults with or atrisk for HIV infection. Antivir Ther 2011; 16: 181-8
6. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 2506-12
7. Galli L, Salpietro S, Pellicciotta G, et al. Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy. Eur J Epidemiol 2012; 27: 657-65
8. Howard AA, Hoover DR, Anastos K, et al. The effects of opiate use and hepatitis C virus infection on risk of diabetes mellitus in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2010; 54: 152-9
9. Butt AA, McGinnis K, Rodriguez-Barradas MC, et al. HIV infection and the risk of diabetes mellitus. AIDS 2009; 23: 1227-34
10. Mehta SH, Moore RD, Thomas DL, Chaisson RE, Sulkowski MS. The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons. J Acquir Immune Defic Syndr 2003; 33: 577-84
11. Monroe AK, Dobs AS, Xu X, et al. Sex hormones, insulin resistance, and diabetes mellitus among men with or at risk for HIV infection. J Acquir Immune Defic Syndr 2011; 58: 173-80
12. Ledergerber B, Furrer H, Rickenbach M, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV infected participants in the Swiss HIV Cohort Study. Clin Infect Dis 2007; 45: 111-9
13. Brown TT, Tassiopoulos K, Bosch RJ, Shikuma C, McComsey GA. Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care 2010; 33: 2244-9
14. Meininger G, Hadigan C, Laposata M, et al. Elevated concentrations of free fatty acids are associated with increased insulin response to standard glucose challenge in human immunodeficiency virus-infected subjects with fat redistribution. Metabolism 2002; 51: 260-6
15. Samaras K. Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 50: 499-505
16. Hruz PW. Molecular mechanisms for insulin resistance in treated HIVinfection. Best Pract Res Clin Endocrinol Metab 2011; 25: 459-68
17. Capeau J, Bouteloup V, Katlama C, et al. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS 2012; 26: 303-14
18. Erlandson KM, Kitch D, Tierney C, et al. Impact of randomized antiretroviral therapy initiation on glucose metabolism. AIDS 2014; 28: 1451-61
19. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-Analysis of randomised statin trials. Lancet 2010; 375: 735-42
20. McComsey GA, Jiang Y, Erlandson KM, et al. Rosuvastatin improves hip bone mineral density but worsens insulin resistance [CROI abstract 134]. In: Special Issue: Abstracts From the 2014 Conference on Retroviruses and Opportunistic Infections. Top Antivir Med 2014; 22(e-1): 34
21. Lichtenstein K, Debes R, Wood K, et al. Statin use is associated with incident diabetes mellitus among patients in the HIV Outpatient Study. In: 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, 3-6 March 2013. Abstract 767
22. Spagnuolo V, Galli L, Poli A, et al. Association between statin use and type-2 diabetes mellitus occurrence among HIV-1+ patients receiving ART. In: 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, 3-6 March 2013. Abstract 766
23. Wang KL, Liu CJ, Chao TF, et al. Statins, risk of diabetes, and implications on outcomes in the general population. J Am Coll Cardiol 2012; 60: 1231-8
24. Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012; 380: 565-71
25. American Diabetic Association. Standards of medical care in diabetes-2014. Diabetes Care 2014; 37(suppl. 1): S14-80
26. Bonora E, Tuomilehto J. The pros and cons of diagnosing diabetes with A1C. Diabetes Care 2011; 34(suppl. 2): S184-90
27. Kim PS, Woods C, Georgoff P, et al. Hemoglobin A1c underestimates glycemia in HIV infection. Diabetes Care 2009; 82: 1591-8
28. Diop M-E, Bastard J-P, Meunier N, et al. Inappropriately low glycated hemoglobin values and hemolysis in HIV-infected patients. AIDS Res Hum Retroviruses 2006; 22: 1242-7
29. Polgreen PM, Putz D, Stapleton JT. Inaccurate glycosylated hemoglobin A1C measurements in human immunodeficiency virus-positive patients with diabetes mellitus. Clin Infect Dis 2003; 37: e53-6
30. Glesby MJ, Hoover DR, Shi Q, et al. Glycated hemoglobin in diabetic women with and without HIV infection: data from the women's interagency HIV study. Antivir Ther 2010; 15: 571-7
31. Slama L, Palella F, Abraham A, et al. Inaccuracy of hemoglobin A1c among HIV-infected: effects of CD4 cell count, antiretroviral therapies, and hematologic parameters. J Antimicrob Chemother 2014; doi: 10.1093/jac/dku295
32. Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2014; 58: e1-34
33. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Table 3. Available at: http://aidsinfo.nih.gov/ContentFiles/AdultandAdoles centGL.pdf. Accessed 25 July 2014
34. Inzucchi S, Bergenstal R, Buse J, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-96
35. Pi-Sunyer X, Blackburn G, Brancati F, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007; 30: 1374-83
36. Esposito K, Maiorino MI, Ciotola M, et al. Effects of a Mediterraneanstyle diet on the need for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: a randomized trial. Ann Intern Med 2009; 151: 306-14
37. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Tables 14 and 15. Available at: http://aidsinfo.nih.gov/ContentFiles/Adultand AdolescentGL.pdf. Accessed 25 July 2014
38. Jensen MD, Ryan DH, Hu FB, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. Circulation 2014; 129(suppl. 1): S102-38
39. Granner ML, Sharpe PA, Hutto BE, Wilcox S, Addy CL. Perceived individual, social, and environmental factors for physical activity and walking. J Phys Act Health 2007; 4: 278-93
40. Bravata DM, Smith-Spangler C, Sundaram V, et al. Using pedometers to increase physical activity and improve health. JAMA 2007; 298: 2296-304
41. Grandes G, Sanchez A, Sanchez-Pinilla RO, et al. Effectiveness of physical activity advice and prescription by physicians in routine primary care: a cluster randomized trial. Arch Intern Med 2009; 169: 694
42. Mozaffarian D, Afshin A, Benowitz NL, et al. Population approaches to improve diet, physical activity, and smoking habits a scientific statement from the American Heart Association. Circulation 2012; 126: 1514-63
43. Artinian NT, Fletcher GF, Mozaffarian D, et al. Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults a scientific statement from the American Heart Association. Circulation 2010; 122: 406-41
44. Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-Analysis of randomized clinical trials. Diabetes Obes Metab 2011; 13: 221-8
45. Tivicay (dolutegravir) prescribing information. Available at: http://www.viivhealthcare.com/media/58599/us-tivicay.pdf. Accessed 21 March 2014
46. Mannucci E, Monami M, Lamanna C, Gensini G, Marchionni N. Pioglitazone and cardiovascular risk. A comprehensive meta-Analysis of randomized clinical trials. Diabetes Obes Metab 2008; 10: 1221-38
47. Deeg MA, Buse JB, Goldberg RB, et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2007; 30: 2458-64
48. Tungsiripat M, El Bejjani D, Rizk N, et al. Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens. AIDS 2010; 24: 1291-8
49. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone interim report of a longitudinal cohort study. Diabetes Care 2011; 34: 916-22
50. Schernthaner G, Currie CJ, Schernthaner G-H. Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013. Diabetes Care 2013; 36(suppl. 2): S155-61
51. Home P, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009; 52: 2499-506
52. Afrezza prescribing information. Available at: http://www.mannkindcorp. com/product-pipeline-diabetes-Afrezza-micro-site.htm. Accessed 13 October 2014
53. Yki-Järvinen H, Juurinen L, Alvarsson M, et al. Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care 2007; 30: 1364-9
54. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-705
55. US Food and Drug Administration. Byetta safety update for healthcare professionals. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafety InformationforHeathcareProfessionals/ucm190406.htm. Accessed 21 March 2014
56. Patil HR, Al Badarin FJ, Al Shami HA, et al. Meta-Analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol 2012; 110: 826-33
57. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-26
58. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-35
59. Goodwin SR, Reeds DN, RoyalM, Struthers H, Laciny E, Yarasheski KE. Dipeptidyl peptidase IV inhibition does not adversely affect immune or virological status in HIV infected men and women: a pilot safety study. J Clin Endocrinol Metab 2012; 98: 743-51.
60. Onglyza (saxagliptin) prescribing information. Available at: http://packageinserts.bms.com/pi/pi-onglyza.pdf. Accessed 21 March 2014
61. National Institutes of Health. NIH begins recruitment for long-Term study of diabetes drug efficacy. Available at: http://www.nih.gov/news/health/jun2013/niddk-03.htm. Accessed 21 March 2014
62. Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-A randomized placebo-controlled trial. Am Heart J 2013; 166: 217-23
63. Invokana (canagliflozin) prescribing information. Available at: http://www.invokanahcp.com/prescribing-information.pdf. Accessed 21 March 2014
64. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-89
65. Abraira C, Colwell J, Nuttall F, et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med 1997; 157: 181-8
66. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59
67. ADVANCE Collaborative Group; Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-72
68. Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009; 151: 394-403
69. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59
70. Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173: 614-22
71. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-91
72. Grinstein J, Cannon CP. Aspirin resistance: current status and role of tailored therapy. Clin Cardiol 2012; 35: 673-80
73. O'Brien M, Montenont E, Hu L, et al. Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study. J Acquir Immune Defic Syndr 2013; 63: 280-8
74. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507-20
75. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63(25 pt B): 2889-934